FDA NDA · NDA008248

WYAMINE SULFATE

Sponsor: BAXTER HLTHCARE CORP

APPLICATION

NDA008248

TYPE

NDA

ORIGINAL APPROVAL

1951-12-29

LATEST ACTION

1993-02-17

ROUTE

INJECTION

DOSAGE FORM

INJECTABLE

MARKETING STATUS

Discontinued

Products

WYAMINE SULFATEDiscontinued

MEPHENTERMINE SULFATE EQ 15MG BASE/ML · INJECTABLE · INJECTION

WYAMINE SULFATEDiscontinued

MEPHENTERMINE SULFATE EQ 30MG BASE/ML · INJECTABLE · INJECTION

1993-02-17Labeling · Supplement 5 · standardAP

1988-05-31Labeling · Supplement 7 · standardAP

1985-10-23Manufacturing (CMC) · Supplement 6 · standardAP

1978-06-07Manufacturing (CMC) · Supplement 4 · standardAP

1951-12-29Type 3 - New Dosage Form · Original · standardAP

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.